Antiinflammatorische Therapie bei Endometriose

C. Banz, K. Diedrich, Daniela Hornung
In: Gyn�kologische Endokrinologie · 2004 · vol. 2(4) , pp. 223–226 · doi:10.1007/s10304-004-0081-6 · W2490903736
article OA: closed CC0 ⤵ 1 in-corpus citation
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

Current endometriosis treatments suppress ovarian steroids with side effects and recurrence, driving research into anti-inflammatory drugs and immune modulators to treat the disease itself.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 ⓘ

The paper reviews the current rationale for endometriosis treatment, noting that established medical therapy mainly suppresses ovarian steroid synthesis but is limited by side effects of estrogen suppression and by symptom recurrence after stopping treatment. It describes research efforts aimed at new approaches grounded in endometriosis pathogenesis, with particular focus on anti-inflammatory drugs and immune system modulators. The authors suggest that such interventions could potentially address not only symptoms but also the underlying disease process, possibly even preventing it, while the caveat is that the discussion is framed as research directions rather than presenting new patient outcomes. This paper is centrally about endometriosis — it focuses on anti-inflammatory therapeutic strategies as next-step approaches beyond steroid suppression.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK